ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS

Clinical trials for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.

Never miss a new study

Get alerted when new ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear

Sign up with your email to follow new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet recruiting 1

New cell therapy trial targets rare, severe autoimmune disease

Disease control Not yet recruiting

This early-stage study is testing a new type of cell therapy called CC-97540 for people with a severe autoimmune disease called ANCA-associated vasculitis that has come back or hasn't responded to standard treatments. The main goals are to check if the treatment is safe and to se…

Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS

Phase: PHASE1, PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control

Last updated Mar 23, 2026 15:19 UTC

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS

Get alerted when new ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear

New cell therapy trial targets rare, severe autoimmune disease